QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN (NYSE: QGEN) has scheduled its Q2 2025 earnings release and conference call. The company will release its second quarter results on Tuesday, August 5, 2025, after market close at 22:05 Frankfurt time (21:05 London/16:05 New York).
The earnings conference call will be held the following day, Wednesday, August 6, at 15:30 Frankfurt time (14:30 London/09:30 New York). Participants can join through multiple channels including call-back registration, direct dial-in, or audio webcast. A replay of the conference call will be made available afterward.
QIAGEN (NYSE: QGEN) announced significant leadership changes and shareholder-friendly initiatives. Stephen H. Rusckowski, former Chairman, President and CEO of Quest Diagnostics, has been elected as Chairman of the Supervisory Board, succeeding Lawrence A. Rosen who stepped down after 12 years of service.
At the Annual General Meeting (AGM), with 80.4% shareholder representation, all proposed resolutions were approved, including two major financial initiatives: the company's first-ever annual cash dividend of $0.25 per share (approximately $54 million total) and a new synthetic share repurchase authorization of up to $500 million.
Following the AGM, QIAGEN's Supervisory Board now consists of eight members, implementing a planned reduction to historical levels while maintaining necessary expertise for the company's future development.
QIAGEN (NYSE: QGEN) has announced a commercial partnership with ID Solutions, a French provider of digital PCR assays, to expand its oncology research portfolio. The collaboration combines QIAGEN's global reach and automation expertise with ID Solutions' assay development and manufacturing capabilities. Under the agreement, ID Solutions will manufacture dPCR assays for non-clinical research use on QIAGEN's QIAcuity platforms, optimized to detect multiple mutations in cell-free DNA from plasma and genomic DNA from FFPE tissue.
The partnership will initially focus on European commercialization, with potential for expansion. This strategic move enhances QIAGEN's existing portfolio, which includes PanCancer Kits and over 200 LNA Mutation Assays available through its GeneGlobe platform. The collaboration aims to provide researchers with ready-to-use assays that deliver results in less than a day, supporting faster adoption of dPCR in oncology research.
QIAGEN (NYSE: QGEN) has announced the acquisition of Genoox for $70 million in cash, with potential additional milestone payments of up to $10 million. The acquisition brings Franklin, Genoox's AI-powered cloud platform for clinical decision support in genetic diseases, into QIAGEN's Digital Insights portfolio.
Franklin is currently used by over 4,000 healthcare organizations across 50+ countries and has processed more than 750,000 case interpretations. The platform helps analyze next-generation sequencing (NGS) data and provides real-time, AI-driven insights for clinical decision-making in genetic disorders, cancer treatments, and family planning.
The acquisition is expected to generate approximately $5 million in sales for 2025 with a neutral impact on adjusted EPS. QIAGEN plans to integrate its genomic content, including HGMD, COSMIC, and QKB databases, into the Franklin platform to enhance its interpretive capabilities.
QIAGEN (NYSE: QGEN) has announced upcoming leadership changes in its Supervisory Board. Stephen H. Rusckowski, current Chair of the Nomination & Governance Committee, will succeed Lawrence A. Rosen as Chairman following the Annual General Meeting on June 26, 2025. Rosen, who has served since 2013 and as Chairman since 2020, will step down after the meeting.
Additionally, Prof. Dr. Elaine Mardis, who has served since 2014, will not seek re-election. All other current Supervisory Board members will stand for re-election to one-year terms. Following these changes, the Supervisory Board will be streamlined to eight members, aligning with a plan announced in 2024.
Rusckowski, who joined the board in 2023, brings significant healthcare industry experience as former Chairman, President and CEO of Quest Diagnostics and former CEO of Philips Healthcare.